Why Is Specified Organism Detection Performed?
Total aerobic microbial count (TAMC) and total yeast and mold count (TYMC) indicate a product’s overall microbial quality; however, they do not identify which microorganisms are present. However, from a microbiological safety perspective, the presence of pathogenic species is more critical than the total count. The specified microorganism screening fills this gap and proves that the product does not contain specified pathogens.
The second key function of the analysis is regulatory compliance. Pharmacopoeia monographs clearly define which pathogens must be screened for in non-sterile products and that these must not be present. The product’s pharmacopoeia compliance, batch release decision, and marketing authorization dossier are based on this data. Third, the analysis is an integral part of raw material and supplier qualification. Raw materials of natural origin, plant extracts, and components of animal origin carry variable risks of contamination; therefore, screening for pathogens during incoming inspection ensures that risks entering the production process are controlled at their source.
Finally, analysis is used to evaluate deviations in the production process. The detection of a specified microorganism requires the initiation of a systematic investigation into the raw material source, water system, environmental controls, or hygiene practices. In this regard, analysis is not merely a compliance check but also an effective quality management tool.
In Which Products Is the Specified Microorganism Searched For?
The analysis covers all non-sterile products subject to microbiological quality requirements. Which pathogens are tested for is determined based on the product’s route of administration, physical form, and the requirements defined in the pharmacopeia monograph. The table below summarizes the main product groups and the microorganisms typically tested for in these groups.
| Product Group | Examples | Microorganisms Typically Sought |
|---|---|---|
| Herbal medicinal products | Herbal teas, extracts, tinctures, powdered mixtures | Escherichia coli, Salmonella spp., bile-tolerant Gram-negative bacteria |
| Oral solid dosage forms | Tablets, capsules, granules, powders | E. coli, Salmonella spp., Staphylococcus aureus |
| Topical and semi-solid forms | Creams, ointments, gels, lotions | Pseudomonas aeruginosa, S. aureus, Candida albicans |
| Raw materials and excipients | Active ingredients, excipients, naturally derived components | Determined based on the product’s source and monograph; frequently E. coli, Salmonella spp. |
| Dietary supplements and natural products | Supplements in capsule, tablet, and powder forms | E. coli, Salmonella spp., S. aureus |
| Cosmetic products | Skin care and personal care products (within the scope of the relevant standard) | P. aeruginosa, S. aureus, C. albicans, E. coli |
Pharmacopoeial Framework: Ph. Eur. 2.6.13 and USP <62>
Ph. Eur. 2.6.13 (Microbiological testing of non-sterile products: screening for specified microorganisms) and USP <62> (Testing for specified microorganisms in non-sterile products) have been made largely compatible as a result of harmonization efforts. Therefore, for products intended for global markets, the requirements of both pharmacopoeias can be met with a single study.
Both texts require that the validity of the assay be demonstrated with respect to the product’s own antimicrobial properties. If the product contains components that inhibit microbial growth, the appropriate dilution or neutralization approach must be validated; results obtained without such validation are not considered valid. The texts also specify that the list of microorganisms to be tested varies depending on the product’s route of administration and that monograph-specific requirements take precedence. Acceptance criteria, however, are not defined in these texts but are specified according to product category under Ph. Eur. 5.1.4 and USP <1111>.
The practical implication of this framework is as follows: The specified microorganism screening must be evaluated in conjunction with the TAMC/TYMC results. Total count alone does not prove the absence of pathogens; similarly, pathogen screening alone does not indicate the overall microbial load. The two sets of data complement each other and together form the product’s microbiological quality profile.
Let’s work together to determine which pathogens need to be screened for in your product, under which pharmacopeia text, and within what scope. Our laboratory’s team of experts will accelerate your regulatory process by defining an analytical strategy tailored to your product group and target market. Contact us to learn more and plan your project.










